Meet the DM Drug Developers: AMO Pharma

March 5th, 2021
12:00 PM Pacific

Click Here to Register!

Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions.

In August 2020, AMO Pharma published the results of a Phase 2 study utilizing AMO-02 (Tideglusib) for Childhood Onset DM1 in Pediatric Neurology. We are excited to announce AMO Pharma will be moving forward with the REACH-CDM Clinical Trial for AMO-02 after the US FDA and Health Canada approved their recently revised study protocols. Click here to learn more about AMO Pharma.

Click here to find all our upcoming Meet the DM Drug Developers dates!


Friday, March 5, 2021
Home / Meet the DM Drug Developers: AMO Pharma

© Myotonic Dystrophy Foundation. All rights reserved.